NuVasive Launches MAGEC X for Early Onset Scoliosis Treatment in the UK

NuVasive Inc., a company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced the United Kingdom (U.K.) launch of MAGEC X, the newest product generation within the MAGEC pediatric portfolio that addresses early-onset scoliosis (EOS).
 
The development of MAGEC X is distinguished by the inclusion of 5.0mm diameter patient rods, delivering a 68 percent improved fatigue-strength performance over the traditional 4.5mm option.¹ It also incorporates several advanced rod mechanisms, most notably a robust actuator seal designed to help further contain and reduce the release of titanium wear debris. Additionally, the rod includes an anti-jam feature to simplify intraoperative and postoperative rod lengthening. Key aesthetic improvements, such as laser-marked sagittal bending lines, help to enhance surgeon workflow efficiency and ease of use.
 
“I am extremely impressed with the NuVasive MAGEC X 5.0mm solution and its ability to provide superior rod strength without having to sacrifice the ideal fixation size thus meeting the clinical needs of pediatric patients,” said Dr. Stewart Tucker, MBBS, FRCS, orthopedic surgeon at Great Ormond Street Hospital in London, England. “Additionally, MAGEC X substantially improves intra-op workflow with enhanced ease of use. It provides surgeons with tremendous flexibility, enabling upsizing of rods while maintaining small screw heads, giving optimal profile and soft tissue cover.”
 
The 5.0mm growing rod in the MAGEC X system pairs with the NuVasive Reline Small Stature fixation system, the first pediatric deformity fixation solution that combines rod strength with low-profile implants. Together, the two systems help minimize the occurrence of revision surgeries by adding enhanced construct strength with an optimized low-profile for EOS patients.
 
“Following in the footsteps of our proven MAGEC solution, MAGEC X brings several new capabilities to the MAGEC portfolio and is a testament to NuVasive’s continuing practice of innovating and delivering next-generation spinal technologies for surgeons and patients in the pediatric space,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “MAGEC X’s 5.0mm rod is truly game-changing as it supports patients with a small implant profile, but with significantly increased fatigue strength over the previous generation.”
 
This U.K. commercial launch of MAGEC X follows the company’s U.S. commercial launch which occurred in July 2018. The company will also host a MAGEC Users Meeting in Lisbon, Portugal on November 16, 2018, following the International Congress on Early Onset Scoliosis (ICEOS) Annual Meeting. This global users meeting will bring together surgeons and surgical staff from around the world to discuss challenges, shared successes, and review best practices related to the use of MAGEC as a treatment for EOS.
 
Reference
¹ Data on File: TR 9604057; dynamic 4-point bending testing per ASTM F2193.